Coherus and Baxalta announce that a Phase 3 clinical trial comparing their biosimilar candidate to Amgen's Enbrel (etanercept), CHS-0214, in patients with rheumatoid arthritis met its primary endpoint of demonstrating equivalence
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?